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BacKGrOund: prOcesses OF rna inTerFerence
Initially postulated by Francis Crick, the central dogma of 
molecular biology outlines the flow of genetic information 
through transcription of double-stranded DNA into single-
stranded messenger RNA (mRNA), followed by translation into 
proteins, yielding the building blocks of life. The processes 
of transcription and translation are regulated by numerous 
molecular pathways, resulting in complex and sophisticat-
ed modifications to this linear process from gene to protein. 
However, in the late 1990s, researchers demonstrated the abil-
ity of certain RNA molecules to reduce the expression of par-
ticular genes through a process now collectively termed RNA 
interference (RNAi) (Fire et al., 1998). Since its initial discovery 
in the laboratory worm Caenorhabditis elegans, small interfer-
ing RNA (siRNA) has been used to impact gene expression in 
research laboratories around the world as an extraordinarily 
powerful genetic tool in biology and medicine for the eluci-
dation of molecular pathways in organismal development and 
human disease.
RNAi takes advantage of the fundamental principle of 
complementary base pairing between nucleic acids, such as 
in DNA–DNA and RNA–DNA double helices. In principle, 
RNAi is a natural process within cells, wherein double-strand-
ed microRNA transcripts are expressed and participate in gene 
regulation. In addition, experimental cellular manipulation 
of double-stranded RNA serving as siRNAs of 20 to 30 base 
pairs in length (Meister and Tuschl, 2004) can be designed 
according to the complementarity principle to specifically tar-
get a particular gene’s mRNA transcript. Following the same 
mechanism as microRNA-mediated silencing, the experimen-
tally introduced double-stranded RNAs are processed by a 
member of the Dicer enzyme family of RNA endonucleases, 
which trim the double-stranded RNAs into fragments of 21 to 
23 base pairs in length. These double-stranded RNAs are then 
unwound into two short, single-stranded siRNAs (the leading 
and the lagging strands). The lagging strand is degraded intra-
cellularly, whereas the leading strand binds the multicompo-
nent protein complex termed the RNA-induced silencing com-
plex (RISC) in the cellular cytoplasm. When the RNAi-loaded 
RISC complex comes into contact with the complementary 
target gene mRNA transcript, base pairing occurs. This base 
pairing activates the cleavage mechanism of the RISC com-
plex and is catalyzed by a member of the Argonaute protein 
family. The target mRNA transcript is cleaved, rendering it 
untranslatable, and, hence, synthesis of the particular protein 
synthesis is prevented. Given its genetic mechanism of action, 
siRNA is considered a powerful technique for posttranscrip-
tional gene silencing. The regulation of siRNA-mediated RNAi 
is an area of ongoing research.
Technical aspecTs OF sirna
Approaching genetic silencing using siRNA requires knowl-
edge of the target gene’s gene sequence and specifically its 
spliced mRNA transcript that is the intended target. A series 
of siRNAs complementary to regions of the target mRNA 
transcript should be designed and assessed for their indi-
vidual efficacy. When using siRNA as a proof-of-function or 
therapeutic strategy for genetic diseases, researchers tend to 
identify unique sequences within the target mRNA respon-
sible for aberrant function (such as the site of a mutant 
allele) as a template by which to design siRNA with specific 
degradation ability.
WHAT IS siRNA?
•  Small interfering RNA (siRNA) represents a form  
of posttranscriptional gene silencing.
•  siRNAs are designed to bind specific mRNA 
molecules and target them for degradation.
•  Common targets of siRNAs include mRNA 
transcripts of mutant genes underlying genetic 
disorders, as well as normal genes involved in the 
cell replication process that are overexpressed in 
cancer cells.
LIMITATIONS 
•  Delivery of siRNAs into cells in vitro by transfection 
is a complex process with variable success.
•  Translating siRNAs for therapeutic purposes into 
humans is complicated by factors of appropriate 
delivery to target cells and stimulation of host 
immune responses.
•  Measuring and quantifying in vivo effects of 
therapeutic siRNA are challenging.
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modification of the synthesized RNA. Quantification gene 
silencing efficacy can be measured using several techniques, 
including real-time quantitative PCR (qPCR) to assess target 
mRNA transcript levels (Garibyan and Avashia, 2013) and 
Western blotting analysis to address effects on protein levels 
(Nicholas and Nelson, 2013). The methodology of siRNA-
mediated RNAi is summarized in Figure 1.
applicaTiOns OF sirna in dermaTOlOGY research
The advantage of siRNA relies upon gene-specific downregu-
lation to target skin disorders and genodermatoses caused by 
a single dominant gene. Recently, Pendaries and colleagues 
studied the potential of siRNA as a modality to inhibit abnor-
mal collagen synthesis in a cellular model of dominant 
dystrophic epidermolysis bullosa (DDEB) (Pendaries et al., 
2012). DDEB, also known as Cockayne–Touraine disease, is 
caused by mutations in the gene COL7A1 encoding a mutant 
type VII collagen α1 subunit that fail to assemble appropri-
ately, resulting in generalized persistent blistering of the skin. 
Pendaries and colleagues designed 21 distinct siRNAs tar-
geted against a specific COL7A1 mutation—deletion of exon 
87—associated with DDEB pruriginosa. The siRNAs were 
designed to interfere with the mutant sequence formed at 
the aberrant splice junction of the defective gene. Using siR-
NAs that were delivered into cultured cells with the mutant 
COL7A1 gene as well as normal cells (Figure 2a and 2b), 
11 of the siRNAs were able to achieve >40% inhibition of 
mutant COL7A1 RNA levels. The specificity of these siRNAs 
for downregulating mutant gene expression was further stud-
ied by evaluating their effectiveness in fibroblasts derived 
from DDEB pruriginosa patients in comparison to healthy 
(normal) control patients, demonstrating 40–60% reductions 
in mutant gene expression, with negligible inhibition of wild-
type collagen VII RNA levels (Figure 3). These findings, in 
conjunction with similar reports using allele-specific siRNA 
targeted against keratin 5 mutations in epidermolysis bullosa 
simplex (Atkinson et al., 2011), offer a glimpse of future clini-
cal applications of siRNA techniques in the management of 
chronic blistering skin disease.
In addition to blistering skin diseases, siRNA has been stud-
ied as a potential therapeutic strategy in a variety of other cuta-
neous conditions, including skin cancers. Because tumor cells 
exhibit higher rates of cell proliferation than normal cells, siR-
NAs may be used to target critical components of cell replica-
tion. In 2010, Zuckerman and colleagues examined the M2 
subunit of ribonucleotide reductase (RRM2)—a key protein in 
DNA replication, required for cell proliferation—as a target for 
siRNAs in melanoma cells (Zuckerman et al., 2010). In Figure 
4, the authors demonstrate the efficacy of the targeted siRNA, 
termed siR2B+5, at decreasing the expression of both RRM2 
mRNA and protein relative to control siRNA, as evidenced by 
qPCR and Western blot analysis. The authors confirmed that 
this siRNA interference functionally affected cell proliferation 
by demonstrating decreased cell viability in a variety of mela-
noma cell lines cultured in vitro (Figure 5a) and a dose-depen-
dent response (Figure 5b). Finally, the authors were able to 
show that cotreatment of melanoma cell lines with siRNA and 
temozolomide—a chemotherapeutic DNA alkylating agent that 
Once the siRNAs are available as double-stranded RNAs 
following their chemical synthesis, they must then be intro-
duced into the cells of interest via a process known as trans-
fection. Various methods of transfection are available; a 
common technique involves mixing siRNA with chemical 
lipids to form liposomes, which enables relatively effective 
delivery through cell membranes into the cytoplasm. Once 
the siRNAs are introduced into the cellular cytoplasm, they 
are processed by cellular enzymes as described above and 
can mediate posttranscriptional gene silencing. A major 
challenge to siRNA effectiveness relates to the cytoplasmic 
degradation of siRNAs that can be delayed by chemical 
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Figure 1. summary of steps of the sirna lab technique and intracellular 
mechanism. (a) Identification of target gene DNA leads to design of 
complementary siRNA that will bind to a DNA target site. (b) Transfection of 
siRNA into cells using liposomal reagents. (c) Intracellular mechanism of siRNA.
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interrupts DNA replication—resulted in enhanced antitumor 
effects that were greater than that of either agent alone (Figure 
6). Other researchers have used siRNA conjugated with anti-
tumor nanoparticles to demonstrate efficacy against melanoma 
cells in vitro (Chen et al., 2010). Similar applications of siRNA in 
combination with nanoparticle-deliverable chemotherapeutic 
agents directed against melanoma may show promise as a novel 
means to achieve tumor-targeted treatment in the future.
FuTure direcTiOns
The past decade has seen tremendous growth and use of 
siRNA techniques for gene silencing and targeted drug deliv-
ery. Such laboratory insights have led to early clinical trials 
seeking to translate these bench applications to the bedside. 
However, several limitations of delivering siRNAs therapeuti-
cally in living organisms exist (Pecot et al., 2011). Biological 
barriers include stabilizing siRNAs for intravascular delivery, 
Figure 2. assay for cOl7a1 mrna inhibition by sirnas. (a) The structural 
elements of the COL7A1 gene introduced into the cells. (b) The base-pair 
structures of siRNAs that were studied for silencing the mutant COL7A1 gene in 
DDEB. (c) The efficacy of the 11 siRNAs that demonstrated over 40% inhibition 
of mutant gene expression. Reprinted from Pendaries et al. (2012).
Figure 3. allele-specific inhibition of endogenous COL7A1Δ87 mrna. 
Significant gene silencing by siRNAs of mutant type VII collagen in fibroblasts 
derived from patients with dominant dystrophic epidermolysis bullosa (red 
line) versus fibroblasts derived from healthy control subjects (blue line). 
Adapted from Pendaries et al. (2012).
Figure 4. Knockdown of ribonucleotide reductase subunit-2 (rrm2) 
mrna and protein expression by sirna sir2B+5 in melanoma cells. (a and 
b) The efficacy of siR2B+5, a targeted siRNA directed against the mRNA 
encoding the M2 subunit of ribonucleotide reductase (RRM2), at decreasing 
the expression of both the target mRNA (a) and the RRM2 protein (b) levels 
relative to control siRNA. Adapted from Zuckerman et al. (2010).
Figure 5. In vitro antiproliferative effects of ribonucleotide reductase 
subunit-2 knockdown by sir2B+5 sirna in a panel of melanoma cell lines. 
(a) Decreased cell viability in melanoma cell lines transfected with siR2B+5 
siRNA versus control siRNA. (b) A dose response in cell viability over time 
with increasing concentrations of siRNA resulting in decreased viability. 
Reprinted from Zuckerman et al. (2010).
Figure 6. synergy between sir2B+5 and temozolomide treatment. (a and b) 
Cotreatment of two distinct melanoma cell lines (M202 and HT-144) with 
both siRNA and temozolomide had an antitumor effect that was greater than 
that of either agent alone. Adapted from Zuckerman et al. (2010).
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achieving efficient target tissue penetrance, and limiting off-
target effects of the siRNAs. One significant challenge is limit-
ing host immune recognition of siRNAs resulting in stimulation 
of an inflammatory response; techniques to modify siRNAs to 
adapt to these constraints are currently being developed.
Despite these challenges, application of siRNAs to in 
vivo treatment of human disease has already begun. Phase 
I clinical trials of systemically delivered siRNA using 
nanoparticles to target melanoma have demonstrated early 
promise (Davis et al., 2010). Trials using intradermal injec-
tion of siRNAs developed for the treatment of pachyonychia 
congenita (Smith et al., 2008; Leachman et al., 2010) have 
similarly been initiated in patient groups. One limitation of 
siRNA-based RNAi in clinical trials is accurately assessing 
efficacy on the molecular level. Strategies using qPCR from 
skin samples are one avenue of measurement, but defini-
tive end points for patient surveillance remain to be eluci-
dated (Hickerson et al., 2010). Although still an emerging 
technique, achieving RNAi via siRNAs has already captured 
the attention of researchers and clinicians alike in achieving 
better understanding and more effective therapeutics for a 
spectrum of cutaneous disorders.
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1.  The typical length of sirnas used for gene silencing is:
A.  7 to 9 base pairs.
B.  21 to 23 base pairs.
C. 36 to 38 base pairs.
D.  55 to 57 base pairs.
2.  sirnas are considered what form of gene  
expression modification?
A.  Transposon-mediated gene silencing.
B.  Histone-mediated gene silencing.
C.  Posttranscriptional gene silencing.
D. Posttranslational gene silencing.
3.  The process of introducing sirnas into cells  
is known as:
A. Transposition.
B.  Translation.
C.  Translocation.
D.  Transfection.
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